Takashi M, Zhu Y, Nakano Y, Miyake K, Kato K
Department of Urology, Nagoya University School of Medicine, Japan.
Urol Res. 1992;20(4):307-11. doi: 10.1007/BF00300265.
To clarify whether serum aldolase A is a useful biomarker for renal cell carcinoma (RCC), we determined serum levels of the aldolase A isozyme by an enzyme immunoassay in patients suffering from RCC, other urological tumors, and benign urological diseases. Forty-six of 126 patients with RCC (37%) had elevated serum aldolase A. The positive rates were 23% in stage I, 40% in stage II, 63% in stage III, and 46% in stage IV. In 10 (83%) of 12 patients whose serum levels had been elevated preoperatively, these were reduced to within the normal range after nephrectomy. Four of 7 patients (57%) with progressive disease had elevated levels of aldolase A. In contrast, the positive rates were only 9.9% in 71 patients with other urological tumors and 5.8% in 52 cases of benign urological diseases. High concentrations of aldolase A isozyme in RCC tissues might be reflected in elevated serum levels. The present findings indicate that serum aldolase A is a useful biomarker for monitoring the clinical course of patients with RCC.
为了明确血清醛缩酶A是否为肾细胞癌（RCC）的有用生物标志物，我们通过酶免疫测定法测定了RCC患者、其他泌尿系统肿瘤患者及泌尿系统良性疾病患者血清中醛缩酶A同工酶的水平。126例RCC患者中有46例（37%）血清醛缩酶A升高。I期阳性率为23%，II期为40%，III期为63%，IV期为46%。12例术前血清水平升高的患者中有10例（83%）在肾切除术后降至正常范围内。7例疾病进展患者中有4例（57%）醛缩酶A水平升高。相比之下，71例其他泌尿系统肿瘤患者的阳性率仅为9.9%，52例泌尿系统良性疾病患者的阳性率为5.8%。RCC组织中高浓度的醛缩酶A同工酶可能反映在血清水平升高上。目前的研究结果表明，血清醛缩酶A是监测RCC患者临床病程的有用生物标志物。
